Sivik Global Healthcare’s Impax Laboratories, Inc. IPXL Stock Holding History

Sivik Global Healthcare’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-165,000	Closed	-$3.35M	–	88
2017 Q3	$3.35M	Sell	165,000 -85,000	-34%	-$1.62M	1.14%	34
2017 Q2	$4.03M	Buy	250,000 +81,970	+49%	+$1.21M	1.47%	31
2017 Q1	$2.13M	Buy	168,030 +63,030	+60%	+$761K	0.99%	42
2016 Q4	$1.39M	Sell	105,000 -25,000	-19%	-$427K	0.66%	47
2016 Q3	$3.08M	Buy	+130,000	New	+$3.49M	1.55%	30
2016 Q1	–	Sell	-47,369	Closed	-$2.02M	–	69
2015 Q4	$2.02M	Sell	47,369 -2,631	-5%	-$105K	0.96%	49
2015 Q3	$1.76M	Sell	50,000 -5,669	-10%	-$255K	0.85%	48
2015 Q2	$2.56M	Buy	55,669 +15,669	+39%	+$744K	0.89%	45
2015 Q1	$1.88M	Sell	40,000 -9,600	-19%	-$382K	0.64%	63
2014 Q4	$1.57M	Buy	+49,600	New	+$1.45M	0.64%	62
2014 Q3	–	Sell	-50,000	Closed	-$1.5M	–	81
2014 Q2	$1.5M	Buy	+50,000	New	+$1.35M	0.76%	53

Other funds holding IPXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sivik Global Healthcare's IPXL Position: Q4 2017 in Review

Sivik Global Healthcare sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 165,000 shares — an estimated $3.35M sold.

Sivik Global Healthcare first reported a position in IPXL in Q2 2014 and held it in 11 quarters. The position peaked at $4.03M in Q2 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Sivik Global Healthcare reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Sivik Global Healthcare sold 165,000 Impax Laboratories, Inc. shares in Q4 2017, an estimated $3.35M.
Sivik Global Healthcare first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 11 quarters.
Sivik Global Healthcare's Impax Laboratories, Inc. position peaked at $4.03M in Q2 2017.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Sivik Global Healthcare's 13F filing for Q4 2017, filed 8 Feb 2018.